<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04918862</url>
  </required_header>
  <id_info>
    <org_study_id>MS-380-2020</org_study_id>
    <nct_id>NCT04918862</nct_id>
  </id_info>
  <brief_title>A COMPARATIVE STUDY BETWEEN 1MG AND 3 MG OF GRANISETRON IN THE PREVENTION OF POSTOPERATIVE NAUSEA AND VOMITING IN STRABISMUS OPHTHALMIC SURGERIES DURING GENERAL ANESTHESIA</brief_title>
  <official_title>A Comparative Study of 1mg and 3 mg of Granisetron in the Prevention of Postoperative Nausea and Vomiting in Strabismus Ophthalmic Surgeries During General Anesthesia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Cairo University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Mohamed Yousry Mohamed</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Tamer Fayez Safan</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Tamer Mohamed Khair</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Mohamed, Ahmed A., M.D.</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Islam Mohamed Sayed</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Cairo University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Investigators aim to determine the optimal dose of granisetron in strabismus ophthalmic&#xD;
      surgeries under general anesthesia to prevent postoperative nausea and vomiting&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Postoperative nausea and vomiting (PONV) are common and distressing symptoms after surgery&#xD;
      under general anesthesia. Despite advances in balanced anesthesia in recent decades, PONV can&#xD;
      result in delayed discharge from the Post-Anesthesia Care Unit (PACU) recovery room,&#xD;
      unexpected hospitalization and increase in medical costs.&#xD;
&#xD;
      The latest class of antiemetic for the prevention and treatment of PONV are the serotonin&#xD;
      receptor antagonists (ondansetron, granisetron). These antiemetics do not have the negative&#xD;
      effects of the older generations. Headache and dizziness are the main adverse effects of the&#xD;
      serotonin receptor antagonists in the dosages used for PONV .&#xD;
&#xD;
      The FDA approved dose for the prevention of PONV is 1mg. This is based on a dose range study&#xD;
      from Wilson and associates in which 0.1, 1.0, and 3.0 mg were associated with risk ratios for&#xD;
      postoperative vomiting. The majority of studies on granisetron suggest that 3mg is superior&#xD;
      to 1mg for the prevention of PONV, but those were published by a single center and there have&#xD;
      been serious concerns about the validity of the data. In previous studies done on elective&#xD;
      open abdominal surgery or vaginal hysterectomy but not in strabismus ophthalmic surgeries.&#xD;
&#xD;
      The ocular surgery associated with the highest incidence of PONV is strabismus surgery up to&#xD;
      85%. Vomiting after surgery is more likely 2-8hours than immediate postoperatively.&#xD;
      Strabismus is a day case procedure and thus participants have to cope with emesis in the&#xD;
      recovery room, or when traveling, or at home.&#xD;
&#xD;
      In this study, investigators compared two doses of granisetron in strabismus ophthalmic&#xD;
      surgeries under general anesthesia&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">January 8, 2021</start_date>
  <completion_date type="Actual">May 18, 2021</completion_date>
  <primary_completion_date type="Actual">May 9, 2021</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>210 patients were recruited and allocated randomly to receive either granisetron 1.0mg (n =105) or granisetron 3.0mg (n =105). The two groups were compared regarding: demographic data of the patients, hemodynamic parameters including mean arterial pressure and heart rate and percentage of patients with no complain of postoperative nausea and vomiting at first 24 hours.</intervention_model_description>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Single (Participant)</masking>
    <masking_description>Computer-generated sequence will be used for randomization and opaque envelopes will be used for concealment</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>The percent of patients with total control of nausea and vomiting over the first 24 hrs postoperative</measure>
    <time_frame>Up to 24 hours</time_frame>
    <description>The percent of patients with total control of nausea and vomiting over the first 24 hrs postoperative</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Detection of the optimal dose of granisetrone</measure>
    <time_frame>Up to 24 hours</time_frame>
    <description>Detection of the optimal dose of granisetrone/mg</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Detection of either attacks of nausea and vomiting occurred post operatively or not. •</measure>
    <time_frame>Post operatively over the first 24 hrs postoperative .</time_frame>
    <description>Detection of either attacks of nausea and vomiting occurred post operatively or not</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Blood Pressure</measure>
    <time_frame>Up to 24 hours</time_frame>
    <description>Blood Pressure measurment mmHg</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Heart Rate</measure>
    <time_frame>Up to 24 hours</time_frame>
    <description>Heart Rate measurment beat /minute</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">210</enrollment>
  <condition>1mg Vs 3 mg of Granisetron</condition>
  <arm_group>
    <arm_group_label>Granisetron 1 mg</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Granisetron 1 mg: 105 patients received 1mg granisetron</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Granisetron 3 mg</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Granisetron 3 mg: 105 patients received 3mg granisetron</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Granisetron</intervention_name>
    <description>210 patients were enrolled, divided into two groups [Granisetron 1 mg: 105 patients received 1mg granisetron, Granisetron 3 mg: 105 patients received 3mg granisetron]. The two groups were compared in demographic characteristics (age, gender, weight, and height), hemodynamic parameters (MAP and HR), and duration of surgery</description>
    <arm_group_label>Granisetron 1 mg</arm_group_label>
    <arm_group_label>Granisetron 3 mg</arm_group_label>
    <other_name>Granisetron in the prevention of postoperative nausea and vomiting in strabismus ophthalmic surgeries during general anesthesia.</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  • Adult patients &gt; 18 years old.&#xD;
&#xD;
               -  ASA I and II.&#xD;
&#xD;
               -  Patients scheduled for strabismus surgery.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  • ASA class &gt; II.&#xD;
&#xD;
               -  Patients with known hypersensitivity or contraindication to any of the study&#xD;
                  medications.&#xD;
&#xD;
               -  Patients who had chronic nausea and vomiting or experienced retching, vomiting,&#xD;
                  moderate to severe nausea in the preoperative day.&#xD;
&#xD;
               -  Patients who had received an antiemetic drug in the preoperative day.&#xD;
&#xD;
               -  Patients with a body mass index ≥36.&#xD;
&#xD;
               -  Pregnant or breast feeding female patient.&#xD;
&#xD;
               -  Patients with gastrointestinal diseases.&#xD;
&#xD;
               -  Patients with a history of motion sickness, diabetes mellitus, and GIT pathology&#xD;
                  (gastritis, hematemesis, peptic ulcer).&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ahmed A Mohamed, M.D</last_name>
    <role>Principal Investigator</role>
    <affiliation>Cairo University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Ahmed Abdalla Mohamed</name>
      <address>
        <city>Cairo</city>
        <zip>11451</zip>
        <country>Egypt</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Egypt</country>
  </location_countries>
  <verification_date>June 2021</verification_date>
  <study_first_submitted>May 20, 2021</study_first_submitted>
  <study_first_submitted_qc>June 2, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">June 9, 2021</study_first_posted>
  <last_update_submitted>June 16, 2021</last_update_submitted>
  <last_update_submitted_qc>June 16, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">June 21, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Cairo University</investigator_affiliation>
    <investigator_full_name>Ahmed Abdalla</investigator_full_name>
    <investigator_title>Professor of Anesthesia &amp;I.C.U and Pain Clinic, Cairo University</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Strabismus</mesh_term>
    <mesh_term>Vomiting</mesh_term>
    <mesh_term>Postoperative Nausea and Vomiting</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Granisetron</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
    <ipd_description>Till Submission</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

